New findings in PiZZ α1-antitrypsin deficiency-related panniculitis: Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy

Dermatology

Volumn 218, Issue 4, 2009, Pages 370-375

  Gross, B ^a   Grebe, M ^b   Wencker, M ^b   Stoller, J K ^c   Bjursten, L M ^c   Janciauskiene, S ^c  

^a Talecris Biotherapeutics ^*

^b LERNER RESEARCH INSTITUTE   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

1 Antitrypsin; Augmentation therapy; Inflammation; Panniculitis; Polymers

Indexed keywords

ALPHA 1 ANTITRYPSIN; POLYMER;

ADULT; ALLELE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANALGESIA; ARTICLE; BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EMPHYSEMA; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; PANNICULITIS; PATHOGENESIS; PRIORITY JOURNAL; SKIN MANIFESTATION; SKIN NODULE; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMISTRY; GENETICS; PATHOLOGY; PHENOTYPE; SKIN;

ADULT; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; FEMALE; HUMANS; PANNICULITIS; PHENOTYPE; POLYMERS; SKIN;

EID: 67651091349     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000202982     Document Type: Article

References (33)

1. Potempa J, Korzus E, Travis J: The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-15960. (Pubitemid 24209273)
2. Hutchison DC: Natural history of alpha-1-protease inhibitor deficiency. Am J Med 1988; 84: 3-12.
3. Janciauskiene S: Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta 2001; 1535: 221-235.
4. Kalsheker N, Morley S, Morgan K: Gene regulation of the serine proteinase inhibitors alpha1-antitrypsin and alpha1-antichymotrypsin. Biochem Soc Trans 2002; 30: 93-98.
5. Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, Vaughan L, Boswell DR: Structure and variation of human alpha 1-antitrypsin. Nature 1982; 298: 329-334.
6. de Serres FJ: Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122: 1818-1829.
7. Kalsheker NA: Molecular pathology of alpha 1-antitrypsin deficiency and its significance to clinical medicine. QJM 1994; 87: 653-658. (Pubitemid 2160073)
8. Abboud RT, Ford GT, Chapman KR: Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome? Treat Respir Med 2005; 4: 1-8.
9. Yu MH, Lee KN, Kim J: The Z type variation of human alpha 1-antitrypsin causes a protein folding defect. Nat Struct Biol 1995; 2: 363-367.
10. Lomas DA, Evans DL, Finch JT, Carrell R: The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357: 605-607.
11. Crystal RG: Alpha 1-antitrypsin deficiency, emphysema, and liver disease: genetic basis and strategies for therapy. J Clin Invest 1990; 85: 1343-1352.
12. Janciauskiene S, Stevens T, Blanco I: New insights into the protective effects of alpha-1-antitrypsin in chronic obstructive pulmonary disease. Curr Respir Med Rev 2007; 3: 147-158. (Pubitemid 46773922)
13. Warter J, Storck D, Grosshans E, Metais P, Kuntz JL, Klumpp T: Weber-Christian syndrome associated with an alpha-1-antitrypsin deficiency: familial investigation (in French). Ann Med Interne (Paris) 1972; 123: 877-882.
14. McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, Crystal RD: Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Chest 1997; 111: 394-403.
15. Gaillard MC, Bothwell J, Dreyer L: A case of systemic nodular panniculitis associated with M1 (Val213) Z phenotype of alpha-1-protease inhibitor. Int J Dermatol 1997; 36: 278-280. (Pubitemid 27242621)
16. Pinto AR, Maciel LS, Carneiro F, Resende C, Chaves FC, Freitas AF: Systemic nodular panniculitis in a patient with alpha-1-antitrypsin deficiency (PiSS phenotype). Clin Exp Dermatol 1993; 18: 154-155. (Pubitemid 23098405)
17. Irvine C, Neild V, Stephens C, Black M: Alpha-1-antitrypsin deficiency panniculitis. J R Soc Med 1990; 83: 743-744.
18. Ortiz PG, Skov BG, Benfeldt E: Alpha1-antitrypsin deficiency-associated panniculitis: case report and review of treatment options. J Eur Acad Dermatol Venereol 2005; 19: 487-490. (Pubitemid 40946108)
19. Stoller JK, Piliang M: Panniculitis in alpha-1 antitrypsin deficiency: a review. Clin Pulm Med 2008; 15: 113-117.
20. Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, Crystal RG: Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055-1062. (Pubitemid 17047294)
21. Knight KR, Burdon JG, Cook L, Brenton S, Ayad M, Janus ED: The proteinase-antiproteinase theory of emphysema: a speculative analysis of recent advances into the pathogenesis of emphysema. Respirology 1997; 2: 91-95. (Pubitemid 27353513)
22. Soy D, de la Roza C, Lara B, Esquinas C, Torres A, Miravitlles M: alpha-1-Antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax 2006; 61: 1059-1064. (Pubitemid 44852024)
23. Lieberman J: Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 1480-1485.
24. Stoller JK, Aboussouan LS: α1 -Antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax 2004; 59: 708-712.
25. Janciauskiene S, Eriksson S, Callea F, Mallya M, Zhou A, Seyama K, Hata S, Lomas DA: Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin. Hepatology 2004; 40: 1203-1210.
26. Smith KC, Pittelkow MR, Su WP: Panniculitis associated with severe alpha1-antitrypsin deficiency: treatment and review of the literature. Arch Dermatol 1987; 123: 1655-1661.
27. Lomas DA, Mahadeva R: Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J Clin Invest 2002; 110: 1585-1590.
28. Ranes J, Stoller JK: A review of alpha-1 antitrypsin deficiency. Semin Respir Crit Care Med 2005; 26: 154-166.
29. Parmar JS, Mahadeva R, Reed BJ, Farahi N, Cadwallader KA, Keogan MT, Bilton D, Chilvers ER, Lomas DA: Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002; 26: 723-730.
30. Elliott PR, Bilton D, Lomas DA: Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol 1998; 18: 670-674. (Pubitemid 128354139)
31. Mulgrew AT, Taggart CC, Lawless MW, Greene CM, Brantly ML, O'Neill SJ, McElvaney NG: Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 2004; 125: 1952-1957.
32. Mahadeva R, Atkinson C, Li Z, Stewart S, Janciauskiene S, Kelley DG, Parmar J, Pitman R, Shapiro SD, Lomas DA: Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005; 166: 377-386. (Pubitemid 40192574)
33. Chowdhury MM, Williams EJ, Morris JS, Ferguson BJ, McGregor AD, Hedges AR, Stamatakis JD, Pope FM: Severe panniculitis caused by homozygous ZZ alpha1-antitrypsin deficiency treated successfully with human purified enzyme (prolastin). Br J Dermatol 2002; 147: 1258-1261.